

REMARKS

Applicants have made one amendment in addition to the amendments submitted in their last response (submitted on May 5, 2004). Applicants have added claim 43, directed to subject matter suggested by the Examiner (see below). Applicants have submitted this added claim along with the May 5, 2004 amendments in this paper.

Applicants have amended claim 1 and claim 2 to correct minor typographical errors introduced into the claims in applicants' Amendment And Reply To Office Action, dated August 7, 2003 (the "August Amendment").

Applicants have amended claim 28 to indicate that the recited tetrazole group is optionally substituted. Applicants have also amended claim 28 to correct an inadvertent typographical error in the spelling of tetrazole.

None of these amendments adds new matter.

The Advisory Action

The Examiner has maintained the position set forth in his April 21, 2004 Advisory Action. According to the Examiner, claims 8, 12-17, and 30 stand rejected under 35 U.S.C. § 102(e) as being anticipated by Ohmoto et al., U.S. 6,136,834 ("Ohmoto et al.").

The Examiner has indicated that "amending the definition of R to recite, e.g., that the heterocyclic groups

are not aryl groups* would overcome these rejections.
Applicants have added claim 43, directed to such R groups, for
the Examiner's consideration.

Conclusion

In view of the above, applicants request that the
Examiner enter the above amendments, consider the foregoing
remarks, and allow the pending claims to issue.

Respectfully submitted,



Lisa A. Dixon (Reg. No. 40,995)
Attorney for Applicants

VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Telephone: (617) 444-6396
Facsimile: (617) 444-6483